![]() ![]() Where evidence is lacking, we describe how we practice and provide a rationale for our approach. Where evidence is present, we provide a concise summary of the literature and clear recommendations on management. We present 7 vignettes to illustrate common clinical management questions that arise during the course of MGUS. Despite its high prevalence, there is surprisingly limited evidence to inform best clinical practice both at the time of diagnosis and during follow-up. Therefore, long-term follow-up is generally recommended. MGUS is considered an obligate precursor to several lymphoplasmacytic malignancies, including immunoglobulin light-chain amyloidosis, multiple myeloma, and Waldenström macroglobulinemia. Unlike most hematologic conditions in which the diagnosis is intentional and credited to hematologists, the discovery of MGUS is most often incidental and made by nonhematologists. Monoclonal gammopathy of undetermined significance (MGUS) is, in many ways, a unique hematologic entity. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |